Fasting serum lipoproteins were measured in 10 untreated patients with carcinoma of the prostate (Group I), 17 patients with non-malignant urological disorders (Group II), and 12 patients on cyproterone acetate (Group III) and 5 on a long-acting luteinizing hormone-releasing hormone (LHRH) analogue (Group IV) for at least 2 months for carcinoma of the prostate. Total high-density lipoprotein (HDL) cholesterol levels were significantly lower in patients in Group III than all the other groups. Very low-density lipoprotein (VLDL) triglyceride levels were significantly higher in patients in Group III than those in Groups II and IV. These results suggest a potentially adverse effect of cyproterone acetate, but not of the long-acting LHRH analogue, on serum lipids, which is likely to be of relevance only in younger patients.
Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate Introduction Carcinoma of the prostate has long been known to be hormone-sensitive, and to be compatible with prolonged survival. The first attempt to alter the tumour growth-promoting effect of androgens pharmacologically involved the use of stilboestrol. Although there was a reduction in mortality from the carcinoma, this was balanced by an increased mortality from the adverse cardiovascular effects1. Increases in serum lipids with stilboestrol and conjugated oestrogens (Premarin) have also been des-cribed2. In 1973 the synthetic antiandrogenic progesterone cyproterone acetate was successfully introduced as an alternative3. Still more recently, long-acting analogues of LHRH have become available and are being used to treat carcinoma of the prostate4. As progestagenic agents used in the combined oral contraceptive preparation and antiandrogens have both been shown to cause disturbances of serum lipids5'6, the present study was undertaken to compare serum lipoproteins in matched hormonally treated and untreated patients suffering from carcinoma of the prostate.
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Patients and methods
Group I: 10 patients with biopsy-proven carcinoma of the prostate who had not received any treatment. Group II: 17 patients with non-malignant urological disorders. Group III: 12 patients treated for 2 months or more with cyproterone acetate 100mg three times daily for carcinoma of the prostate. Group IV: 5 patients treated with implants of long-acting LHRH (Zoladex) for at least 2 months.
There were no differences in mean body weight, age, renal or liver function between the patient groups, and none of the patients was diabetic.
Blood glucose, urea and electrolytes and liver function tests were measured by standard laboratory techniques on fasting blood samples. HDL was isolated following sodium phosphotungstate precipitation of VLDL and LDL. After ultracentrifugation in the Beckman airfuge, VLDL, HDL2 and HDL3 were isolated and lipid content measured. Lowdensity lipoprotein (LDL) cholesterol and triglyceride levels were obtained by difference.
Significance of differences between groups was assessed by unpaired t tests.
Results
Total HDL cholesterol was significantly lower in the cyproterone acetate-treated groups than all the other groups, and VLDL triglyceride levels were significantly higher in the cyproterone acetatetreated patients than in Groups II and IV (Table 1 ).
Discussion
The HDL changes found in patients treated with cyproterone acetate are similar to those reported following the use of other progestational agents5. The trend to high VLDL triglyceride levels is consistent with the well known inverse relationship between HDL cholesterol and VLDL triglyceride. These changes, if maintained for a prolonged period, would increase the risk of cardiovascular disease7'8. However, as noted by Wallentin and Varenhorst6, these changes represent a much less serious risk than that associated with high-dose oestrogen treatment using either diethylstilbestrol or Premarin. Patients treated with a long-acting LHRH analogue showed no significant changes in their lipoproteins, which would, therefore, on these grounds, appear a safer preparation for long-term treatment of younger patients.
